Responses
Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
FRI0205 Golimumab administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy: long-term clinical, radiographic and safety results, including evaluation of remission using the new acr/eular criteria
Compose a Response to This Article
Other responses
No responses have been published for this article.